Nothing Special   »   [go: up one dir, main page]

CN110935002A - Composition with blood pressure lowering effect and application thereof - Google Patents

Composition with blood pressure lowering effect and application thereof Download PDF

Info

Publication number
CN110935002A
CN110935002A CN201911332420.9A CN201911332420A CN110935002A CN 110935002 A CN110935002 A CN 110935002A CN 201911332420 A CN201911332420 A CN 201911332420A CN 110935002 A CN110935002 A CN 110935002A
Authority
CN
China
Prior art keywords
parts
extract
blood pressure
composition
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201911332420.9A
Other languages
Chinese (zh)
Inventor
廖代平
刘新旗
杨秀华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chongqing Shengao Biochemical Pharmaceutical Co Ltd
Original Assignee
Chongqing Shengao Biochemical Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chongqing Shengao Biochemical Pharmaceutical Co Ltd filed Critical Chongqing Shengao Biochemical Pharmaceutical Co Ltd
Priority to CN201911332420.9A priority Critical patent/CN110935002A/en
Publication of CN110935002A publication Critical patent/CN110935002A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/185—Vegetable proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/41—Crassulaceae (Stonecrop family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/536—Prunella or Brunella (selfheal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969—Polygonatum (Solomon's seal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses a composition with a blood pressure reducing effect, which comprises the following raw material components in parts by weight: 5-15 parts of soybean peptide, 1-3 parts of raspberry extract, 1-3 parts of rhodiola rosea extract, 1-3 parts of polygonatum extract, 1-3 parts of grape seed extract, 1-3 parts of green tea extract, 1-3 parts of moringa oleifera leaf extract, 0.5-2 parts of theanine, 0.5-2 parts of astaxanthin, 0.5-2 parts of lycopene, 0.5-2 parts of resveratrol, 0.5-2 parts of curcumin, 0.1-1 part of EPA, 0.1-1 part of DHA, 0.1-1 part of cyanidin and 0.1-1 part of delphinidin; the synergistic antihypertensive drug can not only play a role in lowering blood pressure and effectively reduce the blood pressure of a hypertensive so as to keep the blood pressure of the hypertensive in a stable state for a long time, but also play a role in synergistic effect in lowering cholesterol and blood fat and improving the antioxidant function, relieve and improve the functions of blood vessels, improve the immunity of organisms, remove substances deposited in the blood vessels and blocking the blood vessels, and relieve and improve the occurrence and development of hypertension.

Description

Composition with blood pressure lowering effect and application thereof
Technical Field
The invention relates to the field of medicines, health-care products or foods, in particular to a composition with a blood pressure reducing effect and application thereof.
Background
Hypertension is the most common chronic disease and the most major risk factor for cardiovascular and cerebrovascular diseases, and is liable to cause coronary heart disease, stroke, congestive heart failure and renal dysfunction. Hypertension is characterized by one-time illness and lifelong medication. In recent years, with social progress, economic development, personal income increase, life is gradually rich, fat and heat in food are increased, traffic is developed, physical activity is reduced, and the incidence rate of hypertension in China is on a trend of rising year by year.
The existing medicines for treating hypertension comprise chemical synthetic medicines and Chinese patent medicines. Commonly used chemical synthetic drugs are: diuretic antihypertensives, vascular smooth muscle dilators, Angiotensin Converting Enzyme Inhibitors (ACEI), calcium antagonists, adrenoceptor blockers, angiotensin II receptor Antagonists (AIIRB), and the like, which mainly aim at hypertension symptoms and achieve the purpose of controlling blood pressure by blocking or relieving the blood pressure increase mechanism of the body, but the regulation mechanism of the body can be destroyed, the side effect of the drugs cannot be avoided, and the patient is easy to have drug dependence. The Chinese patent medicine also has a plurality of defects on the prevention and treatment of hypertension, such as strong dependence on the medicine (similar to synthetic medicine), blood pressure reduction effect to be improved, complex composition and difficult quality control, and part of the Chinese medicine also contains some medicine components harmful to the body, which can be enriched in the human body after long-term use and damage the health of the human body.
Therefore, the composition which has a good blood pressure reducing effect and no side effect and is suitable for being eaten by the hypertensive for a long time has an important significance for the hypertensive.
Disclosure of Invention
In view of the above, the invention provides a composition with a blood pressure lowering effect, which has a good blood pressure lowering effect and no side effect and is suitable for long-term consumption of patients with hypertension.
The composition with the blood pressure reducing effect comprises the following raw material components in parts by weight: 5-15 parts of soybean peptide, 1-3 parts of raspberry extract, 1-3 parts of rhodiola rosea extract, 1-3 parts of polygonatum extract, 1-3 parts of grape seed extract, 1-3 parts of green tea extract, 1-3 parts of moringa oleifera leaf extract, 0.5-2 parts of theanine, 0.5-2 parts of astaxanthin, 0.5-2 parts of lycopene, 0.5-2 parts of resveratrol, 0.5-2 parts of curcumin, 0.1-1 part of EPA, 0.1-1 part of DHA, 0.1-1 part of cyanidin and 0.1-1 part of delphinidin;
further, the paint comprises the following raw material components in parts by weight: 10 parts of peptide, 2 parts of raspberry extract, 2 parts of rhodiola rosea extract, 2 parts of rhizoma polygonati extract, 2 parts of grape seed extract, 2 parts of green tea extract, 2 parts of moringa oleifera leaf extract, 1 part of theanine, 1 part of astaxanthin, 1 part of lycopene, 1 part of resveratrol, 1 part of curcumin, 0.5 part of EPA, 0.5 part of DHA, 0.5 part of cyanidin and 0.5 part of delphinidin;
further, the composition may be supplemented with one or more herbs for ameliorating or treating concurrent symptoms;
further, the composition with the blood pressure reducing effect is applied to the preparation of foods, medicines or health-care products with the blood pressure reducing effect.
One or more Chinese herbal medicines for improving or treating concurrent symptoms, such as eucommia ulmoides, dried orange peel, apocynum venetum, selfheal and the like, can be added into the composition with the blood pressure reducing effect.
The composition can be added with conventional auxiliary materials and prepared into food, medicine or health care products acceptable in medicine, dietetics or health care science according to the conventional process; the health product or medicine can be made into liquid granule, powder, tablet, capsule or other conventional dosage forms.
The conventional auxiliary materials comprise: bulking agent, disintegrating agent, lubricant, suspending agent, binder, sweetener, correctant, antiseptic, etc.
Wherein:
the filler comprises: starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose, etc.;
the disintegrating agent comprises: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, cross-linked sodium carboxymethyl cellulose, etc.;
the lubricant comprises: magnesium stearate, sodium lauryl sulfate, talc, silica, and the like;
the suspending agent comprises: polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methylcellulose, and the like;
the adhesive comprises starch slurry, polyvinylpyrrolidone, hydroxypropyl methylcellulose, etc.;
the sweetener comprises: saccharin sodium, aspartame, sucrose, sodium cyclamate, glycyrrhetinic acid, and the like;
the flavoring agent comprises: sweeteners and various essences;
the preservative comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its salts, benzalkonium bromide, chloroacetidine acetate, eucalyptus oil, etc.
The invention has the beneficial effects that:
when the components are screened, the functional complementation is fully considered, the adopted components have low side effect, the cost is low and the components are easy to obtain, and after the components are compounded according to the proportion, the composition not only can be well absorbed by a human body, but also can fully play the mutual matching and synergistic effect among the components after being absorbed, and the composition with the blood pressure reducing effect, which has good treatment effect, no side effect after long-term eating and good blood pressure control effect, is prepared.
The raspberry extract not only contains effective components capable of reducing blood pressure and regulating blood sugar, but also contains selenium element and various strong antioxidant components necessary for human bodies, and can remove redundant free radicals of the human bodies, enhance the immunity of the human bodies and prevent various cardiovascular diseases; the rhodiola rosea extract can alleviate cardiovascular tissue damage and dysfunction caused by pressure, avoid the problem of blood pressure rise caused by cardiovascular dysfunction and simultaneously improve the oxidation resistance and the immune function of an organism; the rhizoma polygonati extract has the effects of reducing blood pressure and blood fat and can keep the blood pressure in a stable state for a long time; the grape seed extract has the effects of reducing blood pressure and blood fat, scavenging free radicals, enhancing immunity, protecting blood vessels and the like; the active ingredients contained in the green tea extract not only have a certain effect on stabilizing blood pressure, but also can improve the oxidation resistance and the immune function of an organism, promote the self-conditioning function of a human body and prevent and treat the formation of plaque in an artery; the moringa oleifera leaf extract contains all nutrient substances required by a human body, has the effects of reducing blood sugar, blood fat, blood pressure, oxidation resistance and the like, and can enhance the immunologic function of the human body, delay senility and prevent diseases after being eaten for a long time; theanine can effectively reduce spontaneous hypertension; the astaxanthin has the functions of resisting oxidation and enhancing immunity; lycopene has remarkable effects in oxidation resistance, immunity enhancement and the like; resveratrol has antioxidant, antiinflammatory, platelet aggregation inhibiting, and vasoconstriction and diastolic blood pressure regulating effects; curcumin has effects of resisting oxidation, reducing blood lipid, preventing atherosclerosis, and is beneficial for dredging blood vessel; EPA and DHA have the effects of reducing the content of cholesterol and triglyceride, promoting the metabolism of saturated fatty acid in vivo, reducing blood viscosity, promoting blood circulation, improving oxygen supply of tissues to eliminate fatigue, preventing fat from depositing on the vessel wall, and preventing the formation and development of atherosclerosis; the delphinidin can obviously inhibit the dysfunction of vascular endothelial cells, increase the activity of the vascular endothelial cells, inhibit apoptosis, reduce lipid peroxidation and inflammatory reaction, and after the active ingredients are compounded according to a specific proportion, the compound preparation not only can play a role of synergy on reducing blood pressure, effectively reduce the blood pressure of a hypertensive so as to keep the blood pressure of the hypertensive in a stable state for a long time, but also can play a role of synergy on reducing cholesterol and blood fat and improving the antioxidant function, alleviate and improve the functions of blood vessels, improve the immunity of organisms, clear substances deposited in the blood vessels and blocking the blood vessels, and relieve and improve the occurrence and the development of the hypertension.
Detailed Description
The following are specific examples: (please provide the ratio of the component proportions)
Example one
The composition with the blood pressure reducing effect comprises the following raw material components in parts by weight: 5 parts of soybean peptide, 1 part of raspberry extract, 1 part of rhodiola rosea extract, 1 part of sealwort extract, 1 part of grape seed extract, 1 part of green tea extract, 1 part of moringa leaf extract, 0.5 part of theanine, 0.5 part of astaxanthin, 0.5 part of lycopene, 0.5 part of resveratrol, 0.5 part of curcumin, 0.1 part of EPA, 0.1 part of DHA, 0.1 part of cyanidin and 0.1 part of delphinidin.
Example two
The composition with the blood pressure reducing effect comprises the following raw material components in parts by weight: 15 parts of soybean peptide, 3 parts of raspberry extract, 3 parts of rhodiola rosea extract, 3 parts of rhizoma polygonati extract, 3 parts of grape seed extract, 3 parts of green tea extract, 3 parts of moringa leaf extract, 2 parts of theanine, 2 parts of astaxanthin, 2 parts of lycopene, 2 parts of resveratrol, 2 parts of curcumin, 1 part of EPA, 1 part of DHA, 1 part of cyanidin and 1 part of delphinidin.
Implementation III
The composition with the blood pressure reducing effect comprises the following raw material components in parts by weight: 5 parts of soybean peptide, 3 parts of raspberry extract, 1 part of rhodiola rosea extract, 3 parts of rhizoma polygonati extract, 1 part of grape seed extract, 3 parts of green tea extract, 1 part of moringa leaf extract, 2 parts of theanine, 0.5 part of astaxanthin, 2 parts of lycopene, 0.5 part of resveratrol, 2 parts of curcumin, 0.1 part of EPA, 1 part of DHA, 0.1 part of cyanidin and 1 part of delphinidin.
Example four
The composition with the blood pressure reducing effect comprises the following raw material components in parts by weight: 15 parts of soybean peptide, 1 part of raspberry extract, 3 parts of rhodiola rosea extract, 1 part of sealwort extract, 3 parts of grape seed extract, 1 part of green tea extract, 3 parts of moringa leaf extract, 0.5 part of theanine, 2 parts of astaxanthin, 0.5 part of lycopene, 2 parts of resveratrol, 0.5 part of curcumin, 1 part of EPA, 0.1 part of DHA, 1 part of cyanidin and 0.1 part of delphinidin.
EXAMPLE five
The composition with the blood pressure reducing effect comprises the following raw material components in parts by weight: 5 parts of soybean peptide, 2 parts of raspberry extract, 3 parts of rhodiola rosea extract, 1 part of sealwort extract, 2 parts of grape seed extract, 3 parts of green tea extract, 1 part of moringa leaf extract, 1.5 parts of theanine, 2 parts of astaxanthin, 1.5 parts of lycopene, 0.5 part of resveratrol, 2 parts of curcumin, 0.8 part of EPA, 0.3 part of DHA, 0.5 part of cyanidin and 1 part of delphinidin.
EXAMPLE six
The composition with the blood pressure reducing effect comprises the following raw material components in parts by weight: 10 parts of peptide, 2 parts of raspberry extract, 2 parts of rhodiola rosea extract, 2 parts of rhizoma polygonati extract, 2 parts of grape seed extract, 2 parts of green tea extract, 2 parts of moringa oleifera leaf extract, 1 part of theanine, 1 part of astaxanthin, 1 part of lycopene, 1 part of resveratrol, 1 part of curcumin, 0.5 part of EPA, 0.5 part of DHA, 0.5 part of cyanidin and 0.5 part of delphinidin.
In the above examples, examples 2 to 6 all had better effects than example 1
Comparative example 1
The composition with the blood pressure reducing effect comprises the following raw material components in parts by weight: 5 parts of soybean peptide, 1 part of kudzu root, 1 part of rhodiola rosea extract, 1 part of rhizoma polygonati extract, 1 part of grape seed extract, 1 part of green tea extract, 1 part of moringa oleifera leaf extract, 0.5 part of theanine, 0.5 part of astaxanthin, 0.5 part of lycopene, 0.5 part of resveratrol, 0.5 part of curcumin, 0.1 part of EPA, 0.1 part of DHA, 0.1 part of cyanidin and 0.1 part of delphinidin.
Kudzu root is a commonly utilized wind-dispelling and exterior-releasing medicine, and clinical reports show that the kudzu root has a bright and obvious curative effect on treating hypertension accompanied with neck pain. In this example, the blood pressure lowering effect was significantly reduced compared to example 1 by replacing the raspberry extract with pueraria lobata.
Comparative example 2
The composition with the blood pressure reducing effect comprises the following raw material components in parts by weight: 5 parts of soybean peptide, 1 part of raspberry extract, 1 part of rhodiola rosea extract, 1 part of sealwort extract, 1 part of grape seed extract, 1 part of green tea extract, 0.5 part of theanine, 0.5 part of astaxanthin, 0.5 part of lycopene, 0.5 part of resveratrol, 0.5 part of curcumin, 0.1 part of EPA, 0.1 part of DHA, 0.1 part of cyanidin and 0.1 part of delphinidin.
In this example, the blood pressure lowering effect was significantly reduced compared to example 1 after the moringa oleifera leaf extract was removed.
Comparative example 3
The composition with the blood pressure reducing effect comprises the following raw material components in parts by weight: 5 parts of soybean peptide, 1 part of raspberry extract, 1 part of wild chrysanthemum flower, 1 part of sealwort extract, 1 part of grape seed extract, 1 part of green tea extract, 1 part of moringa leaf extract, 0.5 part of theanine, 0.5 part of astaxanthin, 0.5 part of lycopene, 0.5 part of resveratrol, 0.5 part of curcumin, 0.1 part of EPA, 0.1 part of DHA, 0.1 part of cyanidin and 0.1 part of delphinidin.
Wild chrysanthemum flower, flos Chrysanthemi Indici, with the actions of clearing heat and removing toxicity, can induce blood pressure. In this example, the effect of lowering blood pressure was reduced compared to comparative example 1 after replacing the rhodiola rosea extract with wild chrysanthemum.
Comparative example 3
The composition with the blood pressure reducing effect comprises the following raw material components in parts by weight: 5 parts of soybean peptide, 1 part of raspberry extract, 1 part of rhodiola extract, 1 part of loranthus parasiticus, 1 part of grape seed extract, 1 part of green tea extract, 1 part of moringa leaf extract, 0.5 part of theanine, 0.5 part of astaxanthin, 0.5 part of lycopene, 0.5 part of resveratrol, 0.5 part of curcumin, 0.1 part of EPA, 0.1 part of DHA, 0.1 part of cyanidin and 0.1 part of delphinidin.
Parasitic loranthus: dispel wind-damp, tonify liver and kidney, nourish blood and prevent abortion, and are primarily used for treating weak bones and muscles, soreness and weakness of waist and knees and other symptoms caused by arthralgia syndrome of blood failing to nourish the tendons and deficiency of liver and kidney, and are also commonly used for treating liver-yin and kidney-yin deficiency type hypertension. In the present example, the effect of lowering blood pressure was reduced compared to comparative example 1 after replacing the polygonatum sibiricum extract with sang-mi-huan.
Animal experimental examples:
1) 60 rats of the primary hypertension model are taken as test objects and are randomly divided into an experimental group (20), a blank control group (20) and a positive control group (20), the rats of each group have no significant difference before the experiment, the basic blood pressure values of each group are uniform, and the data of the rats of each group before administration are as follows:
systolic blood pressure SBP (mmHg) Diastolic pressure DBP (mmHg) Mean arterial pressure MB (mmHg)
Blank control group 210.85±5.71 161.85±6.78 178.18±6.42
Experimental group 211.13±8.12 161.91±6.01 178.32±6.71
Positive control group 210.48±6.98 160.73±7.65 177.31±7.43
2) The positive control group was fed captopril at 1.0mg/kg (equivalent to 3 times the equivalent dose of human dose) twice daily for one week;
feeding the blank control group with clear water twice a day for one week;
the composition of example 1 was used in the experimental group to prepare 1g of crude drug/kg (equivalent to 3 times of the dose of human), and the administration was completed in three times on the first day, followed by administration of clear water.
One week later, the tail artery blood pressure values of the rats in each group are measured and recorded:
systolic blood pressure SBP (mmHg) Diastolic pressure DBP (mmHg) Mean arterial pressure MB (mmHg)
Blank control group 215.45±9.71 166.15±8.21 182.58±8.71
Experimental group 160.73±5.72 125.61±5.71 137.32±5.71
Positive control group 145.18±9.98 100.93±9.65 115.68±9.76
3) Stopping administration, feeding three groups of rats with clear water, measuring and recording tail artery blood pressure values of the rats in each group after one week:
Figure BDA0002330013800000071
Figure BDA0002330013800000081
therefore, after stopping taking the medicine for one week, the systolic pressure, the diastolic pressure and the mean arterial pressure of the positive control group are obviously increased compared with those before stopping taking the medicine, and the systolic pressure, the diastolic pressure and the mean arterial pressure of the experimental group are reduced compared with those before stopping taking the medicine.
The compositions prepared in the first example and the comparative examples 1 and 2 are taken as test articles, and the blood pressure reduction effects are respectively tested:
1. the test personnel:
200 cases of primary hypertension patients (diagnosis accords with diagnosis standards of Chinese hypertension control guidelines (revised 2010), wherein the cases with systolic pressure of 140-159 mmHg and/or diastolic pressure of 90-99 mmHg are hypertension of grade 1 (mild), the cases with systolic pressure of 160-179 mmHg and/or diastolic pressure of 100-109 mmHg are hypertension of grade 2 (moderate), the cases with systolic pressure of not less than 180mmHg or diastolic pressure of not less than 110mmHg are hypertension of grade 3 (severe), the course of disease is 2-30 years, the cases are randomly divided into 1 experimental group and 3 control groups, 50 cases of each group, and age and gender data of 4 groups of hypertension patients have no statistical difference.
2. The test method comprises the following steps:
the composition prepared in example one was used in experimental group 1, and the compositions prepared in comparative examples one and two were used in comparative group 1 and 2, respectively; the using method comprises the following steps: the preparation is administered 2 times daily after meals for 4 weeks;
the control group 3 takes captopril according to the medication standard, and the treatment course is as follows: 4 weeks.
All patients were restricted in sodium intake, quit smoking and alcohol, exercise properly, and work and rest.
3. Criteria for therapeutic effect
The effect is shown: blood pressure decreased by 10mmHg after treatment and had fallen to the normal range, or by more than 20mmHg, but not reached the normal range;
the method has the following advantages: after treatment, the blood pressure is reduced to a normal range although the blood pressure does not reach 10mmHg, or is reduced by 10-19 mmHg;
and (4) invalidation: the blood pressure drop after treatment does not reach the effective standard.
The total effective rate is (number of effective cases + number of effective cases)/the number of people in each group.
4. Test results and conclusions
Number of effective people Number of effective persons Total effective rate Inefficiency of
Experimental group 1 43 6 98％ 1
Control group 1 20 20 80％ 10
Control group 2 19 18 74％ 13
Control group 3 15 20 70％ 15
Finally, the above embodiments are only for illustrating the technical solutions of the present invention and not for limiting, although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions may be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, and all of them should be covered in the claims of the present invention.

Claims (4)

1. A composition with blood pressure lowering effect is characterized in that: the material comprises the following raw materials in parts by weight: 5-15 parts of soybean peptide, 1-3 parts of raspberry extract, 1-3 parts of rhodiola rosea extract, 1-3 parts of polygonatum extract, 1-3 parts of grape seed extract, 1-3 parts of green tea extract, 1-3 parts of moringa oleifera leaf extract, 0.5-2 parts of theanine, 0.5-2 parts of astaxanthin, 0.5-2 parts of lycopene, 0.5-2 parts of resveratrol, 0.5-2 parts of curcumin, 0.1-1 part of EPA, 0.1-1 part of DHA, 0.1-1 part of cyanidin and 0.1-1 part of delphinidin.
2. The composition with hypotensive effect according to claim 1, characterized in that: the material comprises the following raw materials in parts by weight: 10 parts of peptide, 2 parts of raspberry extract, 2 parts of rhodiola rosea extract, 2 parts of rhizoma polygonati extract, 2 parts of grape seed extract, 2 parts of green tea extract, 2 parts of moringa oleifera leaf extract, 1 part of theanine, 1 part of astaxanthin, 1 part of lycopene, 1 part of resveratrol, 1 part of curcumin, 0.5 part of EPA, 0.5 part of DHA, 0.5 part of cyanidin and 0.5 part of delphinidin.
3. Composition with hypotensive effect according to claim 1 or 2, characterized in that: the composition can be added with one or more Chinese herbal medicines for improving or treating concurrent symptoms.
4. The composition with the blood pressure lowering effect according to claim 1 or 2, for use in the preparation of food, medicine or health product with the blood pressure lowering effect.
CN201911332420.9A 2019-12-22 2019-12-22 Composition with blood pressure lowering effect and application thereof Pending CN110935002A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911332420.9A CN110935002A (en) 2019-12-22 2019-12-22 Composition with blood pressure lowering effect and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911332420.9A CN110935002A (en) 2019-12-22 2019-12-22 Composition with blood pressure lowering effect and application thereof

Publications (1)

Publication Number Publication Date
CN110935002A true CN110935002A (en) 2020-03-31

Family

ID=69912159

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911332420.9A Pending CN110935002A (en) 2019-12-22 2019-12-22 Composition with blood pressure lowering effect and application thereof

Country Status (1)

Country Link
CN (1) CN110935002A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113768004A (en) * 2021-08-18 2021-12-10 福鼎市三余茶业有限公司 White tea seasoning tea containing dried orange peel and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104800608A (en) * 2015-05-06 2015-07-29 天津怡昇园科技发展有限公司 Traditional Chinese herbal medicine composition with hypotensive effect and application thereof
CN104855957A (en) * 2015-04-20 2015-08-26 李燕铭 Antioxidant and anti-aging medicinal and health-care product
CN105395925A (en) * 2015-11-27 2016-03-16 杭州海王生物工程有限公司 Composition with hypotensive and anti-obesity effects based on blood fat reduction

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104855957A (en) * 2015-04-20 2015-08-26 李燕铭 Antioxidant and anti-aging medicinal and health-care product
CN104800608A (en) * 2015-05-06 2015-07-29 天津怡昇园科技发展有限公司 Traditional Chinese herbal medicine composition with hypotensive effect and application thereof
CN105395925A (en) * 2015-11-27 2016-03-16 杭州海王生物工程有限公司 Composition with hypotensive and anti-obesity effects based on blood fat reduction

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
汤健 等: "动物与临床试验) ) ) 评价大豆低聚肽的降血压效果" *
陈逸鹏 等: "辣木叶功效及相关成分研究进展" *
韩加 等: "树莓果实提取物减轻 自发性高血压大鼠氧化应激的作用" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113768004A (en) * 2021-08-18 2021-12-10 福鼎市三余茶业有限公司 White tea seasoning tea containing dried orange peel and preparation method thereof

Similar Documents

Publication Publication Date Title
TWI406666B (en) Niu Zhangzhi for the treatment of diseases
CN103156108B (en) Fortified food for preventing and treating diabetes mellitus and hypertension diseases
AU2017262874A1 (en) Gynostemma pentaphyllum containing health care pharmaceutical composition for preventing hyperlipidemia, hypertension, hyperglycemia, and gout
CN111588042A (en) Dietary nutrition conditioning food for assisting in reducing uric acid and controlling gout
CN108404019A (en) Compound chicory root adjusts the solid articles and preparation method thereof of purine metabolic disturbance
CN106511641A (en) Green plum and natto composition with gout treatment effect and preparation method thereof
CN108524673A (en) A kind of Chinese medicine composition and its application
KR101689259B1 (en) Composition having effects of preventing or recovering fatigue or stress
CN110935002A (en) Composition with blood pressure lowering effect and application thereof
KR101859166B1 (en) A composition for removing hangover comprising an herb extract including ginseng
CN104431772A (en) Flour-made food capable of lubricating intestines and detoxifying and preparation method of flour-made food
CN1907374A (en) Chinese medicinal composition for treating oral disease
CN103977390B (en) A kind of preparation method and its usage of ginger onion medicated wine composition
CN118105451A (en) Medicinal and edible composition for preventing and treating ulcerative colitis and application thereof
CN102614359B (en) Traditional Chinese medicine preparation for treating diabetes and preparation method thereof
CN103798472B (en) A kind of health protection tea and health care's preparation
CN107692087A (en) A kind of sea cucumber intestine health food of secondary buck
CN110876717A (en) Preparation method of product capable of stabilizing blood sugar
KR20210097487A (en) Composition for preventing, improving or treating sleep disorders comprising fucoidan
CN114177163B (en) Medicine for treating hypertension
CN108420072A (en) A kind of compound special meal nutritional food of aided blood pressure-lowering
CN105193993B (en) A kind of Chinese medicine composition with blood fat reducing function and preparation method thereof and purposes
CN110140922A (en) A kind of ripe honey of low temperature wine
CN110755523B (en) Composition for improving hyperglycemia and preparation method thereof
KR102203094B1 (en) Composition for preventing and improving menstrual pain and skin troubles

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination